Fig. 3

High dose of DRα1-mMOG-35-55 reduces demyelination and leukocyte infiltration in female mice with chronic EAE. a High-magnification (×63) plastic-embedded spinal cord cross sections are shown from mice 63 days post-immunization after staining with toluidine blue lateral spinal cord of vehicle- or 1 mg DRα1-mMOG-35-55-treated female C57BL/6 mice. Arrow heads show lesions. Asterisks show degenerating axons. Scale bar is 20 μm. Percentage of damage is shown in the bar graph (right) b Paraffin-embedded sections (×20) were used for assessing demyelination using LFB-PAS and hematoxylin staining at 63 days post-immunization. A few areas of demyelination are marked on the sections from DRα1-mMOG-35-55- or vehicle-treated mice. Scale bar is 200 μm. Percentage of demyelination is shown in bar graph (right). **p ≤ 0.01. Student’s t test. c Frequencies of CD4⁺ and CD11b⁺ cells in spinal cord lumbar section of vehicle- or 1 mg DRα1-mMOG-35-55-treated female C57BL/6 mice as evaluated by immunofluorescent staining. *p ≤ 0.05. Student’s t test